摘要
背景:Meta分析显示血清中不与铜蓝蛋白结合的铜(非Cp Cu,也称为“游离”铜)在阿尔茨海默病(AD)患者中所占百分比较高。在AD患者中,基于非Cp Cu切断分层的遗传异质性维持了铜AD代谢亚型的存在。 目的:为了找到与铜异常相关的AD可检测代谢亚型存在的证据,我们探讨了一个同源性和特征明确的AD人群中神经影像学异质性的假设,该群体分为两组基础非Cp Cu切断。 方法:我们评估了66名患者铜,铜蓝蛋白,非铜绿假单胞菌,总Tau蛋白(h-tau),Thr181磷酸化tau蛋白(P-tau)和β-淀粉样蛋白1-42和APOE4基因型的水平AD患者,并比较“正常”和“高”非Cp铜组中分层的AD患者的脑萎缩和神经血管负荷视觉评分量表的神经影像学指数。 结果:非Cp Cu起源的AD组的分层对于内侧颞叶萎缩,脑室周围高信号,更深的高信号(包括额叶,枕颞叶和颞叶白质高信号),幕下高信号指数,而对于全球性萎缩不同。更具体地说,非高Cp铜组的AD患者全身萎缩的负担较轻(p = 0.042)。 结论:AD组间的神经影像学异质性提示AD存在铜代谢亚型;非铜铜似乎是这种铜AD的好标志。
关键词: 神经影像学异质性,铜不与铜蓝蛋白结合(非铜离子铜),阿尔茨海默病,游离铜,全球萎缩,铜。
Current Alzheimer Research
Title:Patients with Increased Non-Ceruloplasmin Copper Appear a Distinct Sub-Group of Alzheimer's Disease: A Neuroimaging Study
Volume: 14 Issue: 12
关键词: 神经影像学异质性,铜不与铜蓝蛋白结合(非铜离子铜),阿尔茨海默病,游离铜,全球萎缩,铜。
摘要: Background: Meta-analyses show that copper non-bound to ceruloplasmin (non-Cp Cu, also known as ‘free’ copper) in serum is higher in a percentage of Alzheimer's disease (AD) patients. Genetic heterogeneity in AD patients stratified on the basis of non-Cp Cu cut-off sustains the existence of a copper AD metabolic subtype.
Objective: In order to find evidence of the existence of a detectable metabolic subtype of AD associated to copper abnormalities, we explore the hypothesis of a neuroimaging pattern heterogeneity in an homogenous and well characterized AD population classified in two groups by the stratification of patients on the basis non-Cp Cu cut-off.
Method: We assessed levels of copper, ceruloplasmin, non-Cp Cu, cerebrospinal levels of total Tau protein (h-tau), Thr 181 phosphorylated tau protein (P-tau) and β-amyloid 1-42, and APOE4 genotype in 66 AD patients and compared neuroimaging indices of a visual rating scale of cerebral atrophy and neurovascular burden in AD patients stratified in ‘Normal’ and ‘High’ non-Cp Cu groups.
Results: The stratification for non-Cp Cu originated AD groups which did not differ for medial temporal lobe atrophy, periventricular hyperintensities, deeper hyperintensities (including frontal, parietooccipital and temporal white matter hyperintensities), infratentorial hyperintensities indices, while they differed for global atrophy. More specifically, AD patients within the high non-Cp Cu group had a less severe burden of global atrophy (p=0.042).
Conclusion: This neuroimaging heterogeneity between AD groups is suggestive of the existence of a copper metabolic subtype of AD; non-Cp Cu appears a good marker of this copper AD.
Export Options
About this article
Cite this article as:
Patients with Increased Non-Ceruloplasmin Copper Appear a Distinct Sub-Group of Alzheimer's Disease: A Neuroimaging Study, Current Alzheimer Research 2017; 14 (12) . https://dx.doi.org/10.2174/1567205014666170623125156
DOI https://dx.doi.org/10.2174/1567205014666170623125156 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MCI Patients Declining and Not-Declining at Mid-Term Follow-Up: FDG-PET Findings
Current Alzheimer Research SIST-M-IR Activities of Daily Living Items that Best Discriminate Clinically Normal Elderly from those with Mild Cognitive Impairment
Current Alzheimer Research Current Progresses of Novel Natural Products and Their Derivatives/ Analogs as Anti-Alzheimer Candidates: an Update
Mini-Reviews in Medicinal Chemistry Purinergic Signalling and Endothelium
Current Vascular Pharmacology Systemic Oxidative Stress in Older Patients with Mild Cognitive Impairment or Late Onset Alzheimer's Disease
Current Alzheimer Research The Detection of Adverse Events in Randomized Clinical Trials: Can we Really Say New Medicines are Safe?
Current Drug Safety Targeting Xanthine Oxidase by Natural Products as a Therapeutic Approach for Mental Disorders
Current Pharmaceutical Design Evaluation and Management of Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets An Appraisal of Current Pharmacological Perspectives of Sesamol: A Review
Mini-Reviews in Medicinal Chemistry Editorial [Hot topic: Alzheimers Disease Drug Discovery: Aβ and Beyond (Guest Editors: D.W. Shineman and H.M. Fillit)]
Current Alzheimer Research 4Aβ1-15-Derived Monoclonal Antibody Reduces More Aβ Burdens and Neuroinflammation than Homologous Vaccine in APP/PS1 Mice
Current Alzheimer Research Subject Index to Volume 2
Current Vascular Pharmacology Roles of p75NTR in Maintaining Brain Hemostasis and the Implications for p75NTR-targeted Therapies
Current Alzheimer Research Nutrition as a Health Determinant in Elderly Patients
Current Medicinal Chemistry RAGE Signaling in Cell Adhesion and Inflammation
Current Pediatric Reviews Platelet GPIIb/IIIa Receptor Antagonists in Human Ischemic Brain Disease
Current Vascular Pharmacology Treatment of Insulin Resistance in the Neurodegeneration
Recent Patents on CNS Drug Discovery (Discontinued) Modulation of Transient Receptor Potential Vanilloid Subtype 1 (TRPV<sub>1</sub>) and Norepinephrine Transporters (NET) Protect Against Oxidative Stress, Cellular Injury, and Vascular Dementia
Current Neurovascular Research Nitric Oxide Induced Damage and Preventive Effect of Curcumin and Quercetin on Buffalo Brain Cystatin
Current Proteomics Minocycline: Neuroprotective Mechanisms in Parkinsons Disease
Current Pharmaceutical Design